Retina BioBank: Retina Biomarkers for a Deeper Understanding of Vitreoretinal and Systemic Diseases
Launched by GREATER HOUSTON RETINA RESEARCH · Jan 22, 2025
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The RBBK study is a non-interventional, prospective study that will characterize disease state biomarker levels from aqueous humor, vitreous humor, intraoperative tissue and saliva of subjects with various retinal and systemic pathologies.
Participants are eligible to be included in the study only if all of the following criteria apply:
1. Men or women \> 18 years of age
2. Subjects with vitreoretinal disease in at least one eye receiving a retinal treatment intervention
3. Able and willing to provide signed informed consent
The study will consist of a single visit and a retrospective ch...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects with vitreoretinal disease in at least one eye receiving a retinal treatment intervention
- Exclusion Criteria:
- • 1. Prior intraocular or subtenon steroid injection in the study eye within the prior 1 month of signing informed consent
- • 2. Intraocular or refractive surgery in the study eye within 30 days of signing informed consent
- • 3. Systemic anti-VEGF treatment within 90 days of signing informed consent
About Greater Houston Retina Research
Greater Houston Retina Research is a leading clinical trial sponsor dedicated to advancing the field of retinal health through innovative research and comprehensive clinical studies. With a commitment to improving patient outcomes, the organization collaborates with top-tier medical professionals and institutions to investigate new treatment options for various retinal conditions. By prioritizing patient safety and ethical standards, Greater Houston Retina Research aims to contribute valuable insights to the scientific community while fostering the development of cutting-edge therapies that enhance vision care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bellaire, Texas, United States
The Woodlands, Texas, United States
Katy, Texas, United States
Patients applied
Trial Officials
Charles C. Wykoff, MD, PhD
Principal Investigator
Greater Houston Retina Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported